From ₹10.2 to ₹14.9 crore a month —
and B2C to the doorstep of profit.

June to March: the run-rate climbs ₹472 L a month.

Monthly gross margin builds from ₹1,022 L in June to ₹1,494 L at the March exit. The build is deliberate: steady through the monsoon quarter, then compounding hard through Q4 as the levers stack.

Profitable in FY25, invested in FY26, back to breakeven in FY27.

The full-year B2C P&L. GM grows 23% on 35% revenue growth; overheads hold flat as we scale, so GM growth drops toward the bottom line. EBIT-2 recovers ₹19 Cr to −₹1 Cr — the cusp of profit.

The ₹472 L climb, business by business.

Monthly GM added between June and the March exit. Assured delivers over half; Consumer and Prime — both recovering businesses — deliver the next third. Every engine ends the year higher than it starts.

Two groups, eight engines, one platform.

Care Navigation connects patients to providers (Prime, Assured, POC, Reach, Partner API, International). Consumer monetises the patient directly. Monthly GM, June → March exit:

Five shifts that define the year.

FY27 isn't more of the same — it's a change in trajectory. These five shifts turn a −₹20 Cr business into a near-breakeven one.

Assured — the engine that nearly doubles.

Monthly GM grows ₹281 → 545 L between June and March — 56% of the whole B2C climb. The flywheel: more relations → more leads → more walk-ins → more in-patient conversions → more GM to reinvest in supply.

The next five slides unpack the engine: the lever walk that builds ₹276 L of monthly GM, the six numbers, the leads build, and the deep-dives on relations, churn and conversion.

Seven levers build the Assured exit.

The AOP models every lakh of Assured GM growth. Against the May-26 base of ₹269 L/month, seven levers stack to the ₹545 L March exit — GTM net-add is half the story, and the model honestly nets off GM-per-walk-in dilution as the mix shifts.

Read: supply (GTM) and product-led demand (PEDA) are three-quarters of the growth; conversion and marketing compound on top. The −₹63 L mix effect is priced in — growth still nets +₹276 L.

The Assured engine, in six numbers.

Each metric compounds quarter by quarter to the March exit. Volume doubles while conversion holds — the model grows on supply and demand, not on stretching funnel math.

Doubling leads to 1.44 lakh/month.

Four stacked buckets take Assured from 73K (Jun) to 144K leads by March. GTM net-add — more supply generating more leads — is half; the rest is named, sized product and marketing initiatives.

The initiative stack (leads/month at Mar-27):

Relations 6.1K → 9.8K: add more, lose less.

The supply base compounds two ways — a hunting-and-expansion machine adding ~380–490 net relations a month, and a churn programme that stops the leak. Both are modelled into every month of the AOP.

Converting harder: lead → walk-in → IP.

More leads only matter if more convert. The AOP models Lead→Walk-in improving 35% → 37% and walk-in value rising ₹222 → 240 — modest on paper, worth ₹38 L/month of GM by March on the doubled base.

Prime — the cash engine flips its GTM in H2.

Monthly GM recovers ₹284 → 359 L (+26%). The AOP is explicit about the shape: net txn adds stay negative through Q2, flip positive in October, and compound through Q4 — while product mix quietly upgrades underneath.

POC — 91 more clinics, three specialties.

The largest revenue line in B2C (₹790 → 1,032 L/month) on a thin ~6% margin. The AOP grows GM +33% the simple way: steady clinic net-adds every month in three specialty engines, at held unit economics.

Key levers: clinic net-adds (the volume driver) · held conversion per clinic and per-lead pricing · GM-per-lead improving ₹425 → 457 as the mix matures. Dedicated hunting headcount steps up 10 → 12 from July.

Reach — a rebuilt sales engine on a leaner base.

Near-pure-margin advertising revenue troughs in July and rebuilds to ₹241 L by March. The AOP does it with fewer people selling more: headcount drops 119 → 85 while productivity per seller rises 30%.

APIs turn Practo into rails — 5.6× in nine months.

Book, Teleconsult and Cashless APIs let partners transact on Practo's network. Full-stack GM grows ₹6.9 → 38.8 L/month — and most of it lands downstream as Assured and Prime volume, which is exactly the point.

UAE: 2.2× on supply, traffic and conversion together.

The AOP rebuilds UAE from ₹5 L to ₹11 L a month by moving all three levers at once: 68% more live relations, 70% more traffic, and booking-to-walk-in up five points. USA is seeded for FY28.

Consumer +46%: a stronger base, and one big new pool.

Monthly GM grows ₹190 → 278 L by March — the first sustained growth since January 2025. The climb splits cleanly: roughly two-thirds is GLP-1 ramping from zero, one-third is Instant Consult compounding; every other line holds.

The base: Instant Cx is the anchor.

Three-quarters of today's Consumer GM sits in Instant Consult — a ~74%-margin, high-frequency engine. The AOP grows it +19% by exit, funded by a deliberate step-up in marketing and discount investment that stays OM-positive.

GLP-1: from zero to ₹64 L a month in seven months.

The single biggest new line in the FY27 plan — a weight-loss program built with a pharma partner (Eli Lilly / Novo Nordisk). It starts in September and compounds steeply: an 88%-margin engine that supplies most of Consumer's Q4 acceleration.

• Why it works: Practo owns the consult-to-adherence journey — doctor consult, prescription, monitoring and refills — which is where GLP-1 programs win or lose.
• The watch item: regulatory posture on GLP-1 consumer marketing (CDSCO) shapes partner choice and go-to-market; the plan carries a dedicated CAC line so the ramp is bought, not assumed.

Operating margin: ₹561 → 888 L a month.

OM grows +58% June to March — faster than GM — because the plan holds people costs flat and spends marketing only where GM follows. At the exit, OM runs +61% year on year.

The GM we already own but don't yet monetise.

Supply score measures how much value we extract from hunted supply. At ~10% today, lifting it toward 30% unlocks a realistic ₹10.2 Cr/month — mostly by upgrading content and features on profiles we already have.

Platform Excellence: 0.4 → 0.9.

PE is the composite of stability, hygiene, conversion, listing quality and AI interventions — the foundation every lever stands on. It has already moved 0.40 → 0.55 since March; the plan takes it to 0.90 by the exit.

Retention is the compounding moat.

Beyond acquisition, FY27 deepens the base. Four durable metrics decide how much of the growth sticks — all trending the right way, all with explicit March targets.

The standout swing: CRM Outreach OM moves from a −₹190K cost to a +₹1.2M profit centre by March — lifecycle outreach pays for itself and then some. PGS share grows through targeted outreach and new consumer value propositions.

Where the plan can break — and the guardrail.

Four structural risks, each visible in the model itself. Naming them is how the weekly review keeps the plan honest.

How the year sequences.

Quarterly average GM run-rate: ₹1,077 L (Q2) → ₹1,175 L (Q3) → ₹1,402 L (Q4). The plan builds foundations in Q2, flips the recovering engines in Q3, and compounds everything in Q4.